469. Healthcare Resource Utilization (HRU) among Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received Definitive Treatment with an Echinocandin (EC) Across United States (US) Hospitals

Abstract Background Guidelines recommend ECs as preferred agents for C/IC. Although studies demonstrate that the are safe and effective treatment of pts with C/IC, there scant HRU data among hospitalized adult who received an EC This study sought to describe current use patterns outcomes C/IC across US hospitals. Methods A retrospective, multi-centered observational was performed using Premier Healthcare Database (1/2016-4/2019). Inclusion criteria: hospitalized; age ≥ 18 years, presence Candida sp. on clinical culture consistent C/IC; ≥3 days between -2 index discharge. Pts were stratified by Baseline characteristics (EC received, receipt in relation culture, duration) assessed. Outcomes: discharge status (in-hospital death vs location), hospital length stay (LOS) post costs (overall component costs) culture. Results 1,865 met criteria. The mean (SD) 58.9 (19), 48% female, Charlson Comorbidity Index 3.4 (2.7) 55% resided ICU at most common C. albicans (37%), glabrata (28%), parapsilosis (11%), tropicalis (10%). Most had C (66%). characteristic largely similar except sp., duration (Table). Mean greater IC (Table Figure). No differences observed died survived. In-hospital mortality higher IC. additional medical care post-discharge more likely be discharged a home health agency. Conclusion Hospital associated substantial, attributable room board costs. considerable many required long-term facility or agency post-discharge. New options needed mitigate daily Disclosures Thomas Lodise, Jr., Pharm.D., PhD, BioFire Diagnostics: Grant/Research Support|cidara: Advisor/Consultant|cidara: Honoraria|Entasis: Support|Merck: Advisor/Consultant|Merck: Support|Paratek: Advisor/Consultant|Shionogi: Advisor/Consultant|Spero: Advisor/Consultant|Venatrox: Advisor/Consultant Kevin W. Garey, PharmD, MS, Acurx: Support|Seres Health: Support|Summit: Support Brian H. Nathanson, Ph.D., cidara: Support.